Document Detail


Fetal therapy with rhIGF-1 in a rabbit model of intrauterine growth retardation.
MedLine Citation:
PMID:  11421616     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Intrauterine growth retardation (IUGR) may, in part, be due to a deficiency of insulin-like growth factor-1 (IGF-1). The objectives of this study were to determine the relationship between fetal serum IGF-1 levels and fetal and placental size in a rabbit model of IUGR and to compare two techniques of selective, exogenous IGF-1 administration (transamniotic and branch uterine arterial catheter infusion) to growth-retarded fetuses in utero. MATERIALS AND METHODS: Pregnant rabbits (n = 6) had their fetuses harvested near term (31 days) for fetal and placental weighing and serum collection. Growth-retarded fetuses were selectively infused for 7 days with recombinant human IGF-1 (rhIGF-1; 1,440 ng/day) either through a transamniotic catheter (n = 8) or via an adjacent uterine arterial branch catheter (n = 6). Opposite horn runts were sham catheterized, but not infused. At term, the fetal runt pairs and their placentas were harvested and weighed, and their serum was collected. The correlation between fetal and placental weight and endogenous serum IGF-1 was calculated (Pearson coefficient, r), while paired t-tests were used to compare the means between the IGF-1-infused and control groups. RESULTS: There was a significant correlation between fetal (r = 0.4230; P = 0.022) and placental weight (r = 0.4166; P = 0.025) and endogenous serum levels of IGF-1. Transamniotic infusion of rhIGF-1 was associated with an increase in serum IGF-1 level (254 +/- 79 vs 351 +/- 101 ng/ml, P = 0.04) and placental weight (5.4 +/- 2.3 vs 7.1 +/- 3.2 g, P = 0.005), and with a trend toward increased fetal weight between matched fetal runt pairs. Fetal mortality in the uterine arterial catheterized group was 76%, and there was no significant difference in fetal or placental weight or IGF-1 levels between infused and noninfused survivors. CONCLUSIONS: Endogenous fetal serum levels correlate with fetal and placental size in the rabbit IUGR model. Transamniotic administration of rhIGF-1 significantly increases serum IGF-1 levels and placental weight of fetal runts, while uterine vessel catheterization results in prohibitive fetal mortality and does not increase fetal or placental growth or IGF-1 levels.
Authors:
E D Skarsgard; L A Amii; R A Dimmitt; G Sakamoto; M E Brindle; R L Moss
Related Documents :
16580726 - Paradoxical discrepancy between the serum level and the placental intensity of pp5/tfpi...
8855836 - Gastrin-releasing peptide-like immunoreactivity is present in human maternal and fetal ...
15582496 - Morphologic alterations in ovine placenta and fetal liver following induced severe plac...
8445176 - Some placental considerations related to neurodevelopmental and other disorders.
1957886 - Forward shift in the initiation of the nocturnal estradiol surge in the pregnant baboon...
11336716 - Assessment of fetal weight based on ultrasonic femur length after the second trimester.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of surgical research     Volume:  99     ISSN:  0022-4804     ISO Abbreviation:  J. Surg. Res.     Publication Date:  2001 Jul 
Date Detail:
Created Date:  2001-06-25     Completed Date:  2001-08-02     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0376340     Medline TA:  J Surg Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  142-6     Citation Subset:  IM    
Copyright Information:
Copyright 2001 Academic Press.
Affiliation:
Department of Surgery, Lucile Packard Children's Hospital, Palo Alto, California 94025, USA. erik.skarsgard@medcenter.stanford.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amnion
Animals
Catheterization / mortality
Female
Fetal Blood / metabolism
Fetal Death
Fetal Growth Retardation / drug therapy*
Humans
Injections
Injections, Intra-Arterial
Insulin-Like Growth Factor I / administration & dosage,  metabolism,  therapeutic use*
Organ Size / drug effects
Placenta / anatomy & histology
Pregnancy
Rabbits
Recombinant Proteins
Uterus / blood supply
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of tumor necrosis factor-alpha and interleukin-1beta in ischemia-reperfusion injury of the ...
Next Document:  Hypoxia regulates osteoblast gene expression.